SCHEMBL1855764

SCHEMBL1855764

Cc1ccc(NS(=O)(=O)c2cccc(C#CCC(CCc3ccccc3)C(=O)O)c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.46
MMP3 P08254 1/20 0.46
MMP13 P45452 1/20 0.46
ALDH1A1 P00352 4/20 0.44
HDAC8 Q9BY41 3/20 0.44
HTR6 P50406 1/20 0.43
AR P10275 1/20 0.43
PGR P06401 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
LIMK2 P53671 1/20 0.42
GAA P10253 1/20 0.41
HDAC4 P56524 2/20 0.40
HDAC1 Q13547 2/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12630220 0.87 HTR6 (0.43) MMP2MMP3MMP13ALDH1A1HDAC8
SCHEMBL8037792 0.82 HTR6 (0.51) ALDH1A1HDAC8HTR6ARPGR
SCHEMBL1856441 0.80 HTR6 (0.53) ALDH1A1HDAC8HTR6ARPGR
SCHEMBL3467103 0.76 MMP13 (0.46) MMP2MMP3MMP13ALDH1A1HDAC8
SCHEMBL8039484 0.75 HTR6 (0.58) MMP2MMP3HDAC8HTR6MEN1
SCHEMBL12666723 0.74 HTR6 (0.50) ALDH1A1HDAC8HTR6ARPGR
SCHEMBL1855593 0.73 HTR6 (0.54) MMP2MMP3ALDH1A1HTR6MEN1
SCHEMBL12630239 0.72 NAMPT (0.45) ALDH1A1HDAC8HTR6MEN1KMT2A
SCHEMBL1861394 0.72 HTR6 (0.44) ALDH1A1HDAC8HTR6ARPGR
SCHEMBL1855155 0.72 STAT5B (0.37) MMP2MMP3MMP13ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110105544-A1 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2011-05-05 US claimed
WO-2009080722-A2 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2009-07-02 WO claimed
US-20110105544-A1 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2011-05-05 US disclosed
WO-2009080722-A2 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2009-07-02 WO disclosed
WO-2009080722-A2 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105544-A1 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AKR1C3, TPD52L2, HCCS MMP2 2326/4885MMP3 3246/4885MMP13 3116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.